Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis.

ABSTRACT:

Background

Topical Janus kinase (JAK) inhibitors are being developed for the treatment of mild to moderate atopic dermatitis. However, comparative evidence on their safety profiles is still limited.

Aim

This study aimed to compare the relative safety of topic JAK inhibitors in patients with atopic dermatitis.

Method

Phase 2 and 3 clinical trials (RCTs) evaluating the efficacy and safety of topical JAK inhibitors in atopic dermatitis were searched on Medline, EMBASE and clinicaltrials.gov. The following outcomes were considered: any adverse event (AE), serious AEs, AEs leading to treatment discontinuation, any infection, any application site reaction.

Results

Ten RCTs were included in this network meta-analysis. Tofacitinib was associated with a reduced risk of

SUBMITTER: Alves C 

PROVIDER: S-EPMC10366300 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature